Please provide your email address to receive an email when new articles are posted on . SALT LAKE CITY — Sickle cell disease increased risk for transplant-associated thrombotic microangiopathy among ...
Operating expenses fell in Q1 after Omeros sold its experimental drug Zaltenibart asset to Novo Nordisk in the latter half of 2025 for up to $2.1 billion. ・Omeros is now awaiting a European Medicines ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the ...
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology,detailing survival outcomes in adult ...
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication that can occur after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Study finds that despite ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Overall, 55 patients were diagnosed with thrombotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results